home

Home> Latest Approval > Market

Industry News
Latest Approval

Shire Receives European Approval for INTUNIV® (guanfacine hydrochloride prolonged release tablets) as a Non-stimulant ADHD Treatment for Children and Adolescents

Shire Receives European Approval for INTUNIV® (guanfacine hydrochloride prolonged release tablets) as a Non-stimulant ADHD Treatment for Children and Adolescents

MarketPharmacodia.com2015-09-21 00:00 Read 690

Shire today announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant INTUNIV (guanfacine hydrochloride prolonged release tablets) for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.

First Prev 1 2 Next Last Total 2 page To page GO

You may interest

Copyright©2020 药渡经纬信息科技（北京）有限公司电子与信息服务业务经营许可证151001号

京ICP备14047345| 京公安网备11010802017043号 |（京）-经营性-2015-0023（互联网药品信息服务资格证书）

: 药渡APP

: 微信二维码